Pfizer
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges
Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges
Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer
Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market
Pfizer Prepared to Shift Manufacturing to US in Response to Potential Trump Tariffs
Pfizer, Albert Bourla, US manufacturing, Trump tariffs, pharmaceutical industry, reshoring
Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field
Pfizer, Beqvez, hemophilia B, gene therapy, discontinuation, portfolio exit
Ex-CDER chief Patrizia Cavazzoni becomes Pfizers chief medical officer
Patrizia Cavazzoni, Pfizer ‘s, Pfizer, Cavazzoni
Pfizer taps former FDA drug chief Cavazzoni as new CMO
United States Food and Drug Administration, Pfizer, Cavazzoni, Center for Drug Evaluation and Research, Appointments, President brand of dental material
Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations
Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials
BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment
Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy
Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns
Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption